Diagnostics Do Well By Investors
The turbulence that began roiling the stock market in May and which by July had pulled down the prices of almost all technology stocks, hurt diagnostics companies as much as anyone else in the health care industry. But a look at the numbers behind these often ignored or maligned firms show they have fared better than most.
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.